Company / EPS (Diluted)
C4 Therapeutics, Inc. EPS (Diluted) History
FY2022-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest EPS (Diluted)
-$1.52
FY2025
5-year range
-$2.67 / -$1.52
FY2022-FY2025
Trend
+43.1%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
EPS (Diluted) returned to growth in FY2025 after 2 years of decline, reaching $-1.52.
Based on SEC 10-K filings.
-1.52 in FY2025.
Improved from $-2.62 to $-1.52 over the past 2 years.
EPS (Diluted) over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, eps (diluted) increased 43.1% year-over-year.
Company context
Key Data Points
- Altman Z-Score -1.14 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | EPS (Diluted)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$1.52 | +43.1% |
| FY2024 | -$2.67 | -1.9% |
| FY2023 | -$2.62 | -44.0% |
| FY2022 | -$1.82 | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026